Vimarsana
Biggest News Aggregation in the World

Page 4 - Tender Offer Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tender Offer Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tender Offer Statement Today - Breaking & Trending Today

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Vimarsana News

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

EQS-News: MorphoSys AG / Key word: Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update 13.03.2024 / 21:01...

Renesas Extends Tender Offer for Proposed Acquisition of Sequans - Vimarsana News

Renesas Extends Tender Offer for Proposed Acquisition of Sequans

Renesas Electronics Corporation and Sequans Communications S.A. today announced that Renesas has extended the expiration date of its tender offer to acquire all of the outstanding ordinary shares...

Diversified Energy Company announces Return of Capital options for Shareholders - Vimarsana News

Diversified Energy Company announces Return of Capital options for Shareholders

Diversified Energy Company announces the opportunity for shareholders to choose how they receive a US$42 million return of capital.

DIRTT Announces Issuer Bid and Tender Offer to Purchase 6.00% Convertible Debentures due January 2026 and 6.25% Convertible Debentures due December 2026 - Vimarsana News

DIRTT Announces Issuer Bid and Tender Offer to Purchase 6.00% Convertible Debentures due January 2026 and 6.25% Convertible Debentures due December 2026

CALGARY, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics - Vimarsana News

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the ...